Cargando…

Comparative injection-site pain and tolerability of subcutaneous serum-free formulation of interferonβ-1a versus subcutaneous interferonβ-1b: results of the randomized, multicenter, Phase IIIb REFORMS study

BACKGROUND: In patients with relapsing–remitting multiple sclerosis (RRMS), subcutaneous (sc) interferon (IFN)β-1a and IFNβ-1b have been shown to reduce relapse rates. A formulation of IFNβ-1a has been produced without fetal bovine serum and without human serum albumin as an excipient (not currently...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singer, Barry, Bandari, Daniel, Cascione, Mark, LaGanke, Christopher, Huddlestone, John, Bennett, Randy, Dangond, Fernando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3541262/ https://www.ncbi.nlm.nih.gov/pubmed/23216674 http://dx.doi.org/10.1186/1471-2377-12-154

Ejemplares similares

Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1
por: Traboulsee, Anthony, et al.
Publicado: (2018)

Severe Subcutaneous Calcification in an Interferon-β-treated MS Patient
por: Masuda, Hiroki, et al.
Publicado: (2017)

Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β-1a in MS
por: Arnold, Douglas L., et al.
Publicado: (2016)

Predictive value of early magnetic resonance imaging measures is differentially affected by the dose of interferon beta-1a given subcutaneously three times a week: an exploratory analysis of the PRISMS study
por: Traboulsee, Anthony, et al.
Publicado: (2018)

Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study
por: Devonshire, Virginia, et al.
Publicado: (2010)

Subcutaneous interferon β-1a three times weekly and the natural evolution of gadolinium-enhancing lesions into chronic black holes in relapsing and progressive multiple sclerosis: Analysis of PRISMS and SPECTRIMS trials
por: Traboulsee, A, et al.
Publicado: (2017)

Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland
por: Järvinen, Elina, et al.
Publicado: (2019)

Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis
por: Freedman, Mark S
Publicado: (2014)

Patient satisfaction following transition from the original to the new formulation of subcutaneous interferon beta-1a in relapsing multiple sclerosis: a randomized, two-arm, open-label, Phase IIIb study
por: Camu, William, et al.
Publicado: (2010)

Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes
por: De Stefano, Nicola, et al.
Publicado: (2014)

Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a
por: Ben-Amor, Ali-Frédéric, et al.
Publicado: (2015)

Randomized trial of daily high-dose vitamin D(3) in patients with RRMS receiving subcutaneous interferon β-1a
por: Hupperts, Raymond, et al.
Publicado: (2019)

Lost in Translation: Evaluation of Subcutaneous Interferon-β Treatment for SARS-CoV-2 Infection in Real Life
por: Casado, José L., et al.
Publicado: (2022)

Patient assessment of an electronic device for subcutaneous self-injection of interferon β-1a for multiple sclerosis: an observational study in the UK and Ireland
por: D’Arcy, Caroline, et al.
Publicado: (2012)

Patient subgroup analyses of the treatment effect of subcutaneous interferon β-1a on development of multiple sclerosis in the randomized controlled REFLEX study
por: Freedman, Mark S., et al.
Publicado: (2014)

COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects
por: Hu, Xiao, et al.
Publicado: (2016)

A Prospective Multicenter Study for Assessing MusiQoL Validity among Arabic-Speaking MS Patients Treated with Subcutaneous Interferon β-1a
por: Al Jumah, Mohammed, et al.
Publicado: (2021)

Subcutaneous interferon beta-1a in COVID-19: raking the ashes of an intervention trial
por: Wilkinson, Tom
Publicado: (2021)

Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study
por: Zecca, Chiara, et al.
Publicado: (2017)

Interferon-gamma-induced local leukocytoclastic vasculitis at the subcutaneous injection site
por: Wang, Fang, et al.
Publicado: (2016)

Subcutaneous Interferon-β1a Does Not Increase the Risk of Stroke in Patients with Multiple Sclerosis: Analysis of Pooled Clinical Trials and Post-Marketing Surveillance
por: Sabidó, Meritxell, et al.
Publicado: (2018)

RARE-28. The use of subcutaneous interferon in patients with craniopharyngioma: an institutional retrospective review
por: Patil, Prabhumallikarjun, et al.
Publicado: (2022)

Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart(®) in patients with multiple sclerosis
por: Edo Solsona, María Dolores, et al.
Publicado: (2017)

Subcutaneous administration of interferon beta-1a for COVID-19: A non-controlled prospective trial
por: Dastan, Farzaneh, et al.
Publicado: (2020)

Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis
por: Freedman, Mark S., et al.
Publicado: (2021)

Reasons for discontinuation of subcutaneous interferon β-1a three times a week among patients with multiple sclerosis: a real-world cohort study
por: Sabidó-Espin, Meritxell, et al.
Publicado: (2017)

Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study
por: Deftereos, Spyros N., et al.
Publicado: (2018)

IN VITRO ASSESSMENT OF THE BIOLOGIC ACTIVITY OF INTERFERON BETA FORMULATIONS USED FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS
por: Scagnolari, Carolina, et al.
Publicado: (2014)

Subcutaneous Interferon β-1a May Protect against Cognitive Impairment in Patients with Relapsing–Remitting Multiple Sclerosis: 5-Year Follow-up of the COGIMUS Study
por: Patti, Francesco, et al.
Publicado: (2013)

Subcutaneous Interferon β-1a Administration by Electronic Auto-injector is Associated with High Adherence in Patients with Relapsing Remitting Multiple Sclerosis in a Real-life Study
por: Järvinen, Elina, et al.
Publicado: (2017)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review
por: Asif, Abuzar A., et al.
Publicado: (2021)

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial
por: Dwyer, Michael G., et al.
Publicado: (2015)

Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a
por: Vrenken, H., et al.
Publicado: (2023)

EDSS Change Relates to Physical HRQoL While Relapse Occurrence Relates to Overall HRQoL in Patients with Multiple Sclerosis Receiving Subcutaneous Interferon β-1a
por: Vickrey, Barbara G., et al.
Publicado: (2015)

Interferon-β 1a and SARS Coronavirus Replication
por: Hensley, Lisa E., et al.
Publicado: (2004)

Persistence on Therapy and Propensity Matched Outcome Comparison of Two Subcutaneous Interferon Beta 1a Dosages for Multiple Sclerosis
por: Kalincik, Tomas, et al.
Publicado: (2013)

Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-α and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression
por: Ota, H, et al.
Publicado: (2005)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021)

A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis
por: Jaber, Amer, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_7rep5k4928v35kdvuh55tt7dp7